Search Result

Results for "

PDE III

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Phosphodiesterase (PDE) (32) Apoptosis (7) Calcium Channel (1) Drug Metabolite (2) Endogenous Metabolite (1) Isotope-Labeled Compounds (2) PKA (1) Potassium Channel (2) Prostaglandin Receptor (1) Reference Standards (6)
By Research Areas:	Cancer (7) Cardiovascular Disease (27) Inflammation/Immunology (6) Metabolic Disease (2) Neurological Disease (3)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Phosphodiesterase (PDE)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-111673

8-CPT-Cyclic AMP sodium 8-CPT-cAMP sodium; 8-(p-Chlorophenylthio)-cAMP sodium	PKA Phosphodiesterase (PDE)	Inflammation/Immunology
8-CPT-Cyclic AMP (8-CPT-cAMP) sodium is a selective activator of cyclic AMP-dependent protein kinase (PKA). 8-CPT-Cyclic AMP sodium is also a potent inhibitor of the cyclic GMP-specific phosphodiesterase *(PDE* VA) with an IC₅₀** of 0.9 μM. 8-CPT-Cyclic AMP sodium also inhibits PDE III and PDE IV with IC₅₀Epac and is a potent Epac activator .

HY-B0523

Anagrelide 3 Publications Verification	Phosphodiesterase (PDE) Apoptosis	Cardiovascular Disease Cancer
Anagrelide is a potent inhibitor of phosphodiesterase type III (PDE3) (IC₅₀=36 nM). Anagrelide, an imidazoquinazoline derivative, acts as an inhibitor of platelet aggregation. Anagrelide inhibits bone marrow megakaryocytopoiesis. Anagrelide decreases gastrointestinal stromal tumor (GIST) cell proliferation and promotes their apoptosis in vitro. Anagrelide is a platelet-lowering agent and plays in the antithrombopoietic action .

HY-B0523A

Anagrelide hydrochloride 3 Publications Verification BL4162A	Phosphodiesterase (PDE) Apoptosis	Cardiovascular Disease Cancer
Anagrelide hydrochloride (BL4162A) is a potent inhibitor of phosphodiesterase type III (PDE3) (IC₅₀=36 nM). Anagrelide hydrochloride, an imidazoquinazoline derivative, acts as an inhibitor of platelet aggregation. Anagrelide hydrochloride inhibits bone marrow megakaryocytopoiesis. Anagrelide hydrochloride decreases gastrointestinal stromal tumor (GIST) cell proliferation and promotes their apoptosis in vitro. Anagrelide hydrochloride is a platelet-lowering agent and plays in the antithrombopoietic action .

HY-B1639

Enoximone	Phosphodiesterase (PDE)	Cardiovascular Disease Inflammation/Immunology
Enoximone is an inotropic vasodilating agent and a selective and orally active phosphodiesterase III (PDE3) inhibitor with an IC₅₀ of 5.9 μM. Enoximone induces vasodilatation and increases intracellular levels of cAMP by inhibiting cGMP-inhibited PDE. Enoximone also exhibits *PDE4* inhibitory effect with an IC₅₀ of 21.1 μM for myocardial PDE4A. Enoximone has the potential for congestive heart failure research and has bronchodilatory, antiasthma and anti-inflammatory effects .

HY-135746

OR-1896 2 Publications Verification	Potassium Channel Phosphodiesterase (PDE) Drug Metabolite Apoptosis	Cardiovascular Disease
OR-1896 is an active long-lived metabolite of Levosimendan. OR-1896 is a highly selective phosphodiesterase (PDE) III isoform inhibitor and a powerful vasodilator. OR-1896 can open ATP-sensitive K ⁺ channels and has Ca ²⁺-sensitizing effect. OR-1896 mitigates cardiomyocyte apoptosis, cardiac remodeling and myocardial inflammation .

HY-100164

SDZ-MKS 492 MKS 492	Phosphodiesterase (PDE)	Inflammation/Immunology
SDZ-MKS 492 (MKS 492) is a selective inhibitor of cyclic GMP-inhibited phosphodiesterase (type III PDE). SDZ-MKS 492 inhibits antigen- or platelet activating factor (PAF)-induced bronchoconstriction and allergic reactions in guinea pigs and rats .

HY-108621

RS-25344 hydrochloride	Phosphodiesterase (PDE)	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
RS-25344 hydrochloride is a selective *cAMP-phosphodiesterase 4 (PDE* 4; PDE IV) inhibitor with an IC₅₀** of 0.28 nM in human lymphocytes. RS-25344 hydrochloride has only weak inhibitory effects on PDE I, II, III (IC₅₀ of >100 μM, 160 μM, 330 μM, respectively). RS-25344 hydrochloride has anti-inflammatory, memory- and cognition enhancing, and antineoplastic effects .

HY-19026

Siguazodan SKF 94836	Phosphodiesterase (PDE)	Cardiovascular Disease
Siguazodan (SKF 94836) is a potent, selective and orally active phosphodiesterase III (PDE-III) inhibitor with an IC₅₀ of 117 nM. Siguazodan increases cAMP accumulation in intact platelets with an EC₅₀ of 18.88 μM. Siguazodan also inhibits phenylephrine-induced 5-HT release with an IC₅₀ value of 4.2 μM .

HY-B1514R

Allantoic acid (Standard)	Reference Standards Endogenous Metabolite	Others
Anagrelide (hydrochloride) (Standard) is the analytical standard of Anagrelide (hydrochloride). This product is intended for research and analytical applications. Anagrelide hydrochloride (BL4162A) is a potent inhibitor of phosphodiesterase type III (PDE3) (IC50=36 nM). Anagrelide hydrochloride, an imidazoquinazoline derivative, acts as an inhibitor of platelet aggregation. Anagrelide hydrochloride inhibits bone marrow megakaryocytopoiesis. Anagrelide hydrochloride decreases gastrointestinal stromal tumor (GIST) cell proliferation and promotes their apoptosis in vitro. Anagrelide hydrochloride is a platelet-lowering agent and plays in the antithrombopoietic action .

HY-114564

Satigrel E5510	Prostaglandin Receptor	Cardiovascular Disease
Satigrel (E5510) is a potent inhibitor of platelet aggregation. Satigrel inhibits collagen- and arachidonic acid-induced platelet aggregation through preventing thromboxane A2 synthesis by selective inhibition of the target enzyme, PGHS1, which exists in platelets. Satigrel inhibits PGHS1 (IC₅₀: 0.081 μM) and PGHS2 (IC₅₀: 5.9 μM). Satigrel is against Type III PDE, Type V and Type II (IC₅₀: 15.7 μM, 39.8 μM and 62.4 μM, respectively) .

HY-106844

EMD 53998	Phosphodiesterase (PDE)	Cardiovascular Disease
EMD 53998 is a cardiotonic agent that increases myocardial contractility as an inhibitor for phosphodiesterase III (PDE *III*) and a calcium sensitizer. EMD 53998 increases myocardial contractility, reduces energy consumption and the risk of inducing arrhythmias .

HY-153168

Bemoradan	Phosphodiesterase (PDE)	Cardiovascular Disease
Bemoradan (compound 10a) is an orally active and selective canine *Phosphodiesterase (PDE)* fraction III inhibitor. Bemoradan is a long-acting, potent, inotropic vasodilator and a novel cardiotonic agent, and can be used in congestive heart failure research .

HY-120577

BA 41899	Others	Cardiovascular Disease
BA 41899 is a purely calcium-sensitizing agent. BA 41899 is completely devoid of phosphodiesterase (PDE) III inhibitory activity or any other known inotropic mechanism. BA 41899 can be used for the research of cardiovascular diseases, such as congestive heart failure (CHF) .

HY-101644A

Saterinone hydrochloride BDF 8634 hydrochloride	Phosphodiesterase (PDE)	Cardiovascular Disease
Saterinone hydrochloride is a phosphodiesterase III (PDE *III*) inhibitor.

HY-105418

WIN-63291	Phosphodiesterase (PDE)	Cardiovascular Disease
WIN-63291 is a selective and orally active phosphodiesterase (PDE) III inhibitor. WIN-63291 can be used for the research of cardiovascular disease .

HY-115269

CK-2289	Phosphodiesterase (PDE)	Cardiovascular Disease
CK-2289 is an inhibitor of type III cyclic 3'5'-adenosine monophosphate phosphodiesterase (PDE). CK-2289 can inhibit platelet aggregation and decreases mean arterial blood pressure. CK-2289 can be used for the research of cardiovascular disease, such as congestive heart failure .

HY-101644

Saterinone BDF 8634	Phosphodiesterase (PDE)	Cardiovascular Disease
Saterinone is a phosphodiesterase III (PDE *III*) inhibitor.

HY-106474

Meribendan	Phosphodiesterase (PDE)	Neurological Disease
Meribendan is a phosphodiesterase (PDE)-III inhibitor .

HY-U00136

Win-62005	Phosphodiesterase (PDE)	Cardiovascular Disease
Win-62005 is a cyclic AMP phosphodiesterase III (PDE *III) inhibitor with K_i*s of 25 and 26 nM for rat heart and canine aorta, respectively.

HY-106098

Adibendan BM 14478	Phosphodiesterase (PDE)	Cardiovascular Disease
Adibendan (BM 14478), a benzimidazole derivative, is an orally active, selective phosphodiesterase III (PDE III) activity inhibitor (IC₅₀=2.0 μM). Adibendan has IC₅₀ values more than 60-fold higher for the inhibition of PDE I or II. Adibendan is a new cardiotonic agent .

HY-101693A

Senazodan hydrochloride MCI 154 hydrochloride	Phosphodiesterase (PDE)	Cardiovascular Disease
Senazodan (MCI 154) (hydrochloride), as a Ca ²⁺ sensitiser, shows inhibition effect on **PDE III** .

HY-106045

Imazodan CI 914 free base	Phosphodiesterase (PDE)	Cardiovascular Disease
Imazodan is a selective inhibitor for phosphodiesterase III (PDE *III*), which increases myocardial contractility by blocking the cAMP degradation, and improves the contractile function of heart. Imazodan serves also as a peripheral vasodilator .

HY-101693

Senazodan MCI 154	Phosphodiesterase (PDE)	Cardiovascular Disease
Senazodan (MCI 154) is a Ca ²⁺ sensitiser, and also shows inhibition effect on **PDE III** .

HY-106045A

Imazodan hydrochloride CI 914	Phosphodiesterase (PDE)	Cardiovascular Disease
Imazodan hydrochloride is the hydrochloride form of Imazodan (HY-106045). Imazodan hydrochloride is a selective inhibitor for phosphodiesterase III (PDE *III*), which increases myocardial contractility by blocking the cAMP degradation, and improves the contractile function of heart. Imazodan hydrochloride serves also as a peripheral vasodilator .

HY-114990

EMD 57439	Phosphodiesterase (PDE)	Cardiovascular Disease
EMD 57439 is a selective *PDE-III* inhibitor. EMD 57439 does not significantly increase c-AMP concentration and has little effect on Ca(50) .

HY-126763

ATI22-107	Phosphodiesterase (PDE) Calcium Channel	Others
ATI22-107 is a dual-pharmacophore compound designed to simultaneously inhibit cardiac phosphodiesterase (PDE-III) and L-type calcium channels (LTCC), with activity that has specific effects on calcium cycling and contractility in cat ventricular myocytes and trabeculae.

HY-19026R

Siguazodan (Standard) SKF 94836 (Standard)	Phosphodiesterase (PDE) Reference Standards	Cardiovascular Disease
Siguazodan (Standard) is the analytical standard of Siguazodan. This product is intended for research and analytical applications. Siguazodan (SKF 94836) is a potent, selective and orally active phosphodiesterase III (PDE-III) inhibitor with an IC50 of 117 nM. Siguazodan increases cAMP accumulation in intact platelets with an EC50 of 18.88 μM. Siguazodan also inhibits phenylephrine-induced 5-HT release with an IC50 value of 4.2 μM .

HY-B0523B

Anagrelide hydrochloride monohydrate	Phosphodiesterase (PDE) Apoptosis	Cardiovascular Disease Cancer
Anagrelide hydrochloride monohydrate is a potent inhibitor of phosphodiesterase type III (PDE3) (IC₅₀=36 nM). Anagrelide hydrochloride monohydrate, an imidazoquinazoline derivative, acts as an inhibitor of platelet aggregation. Anagrelide hydrochloride monohydrate inhibits bone marrow megakaryocytopoiesis. Anagrelide hydrochloride monohydrate decreases gastrointestinal stromal tumor (GIST) cell proliferation and promotes their apoptosis in vitro. Anagrelide hydrochloride monohydrate is a platelet-lowering agent and plays in the antithrombopoietic action .

HY-B0523AR

Anagrelide hydrochloride (Standard) BL4162A (Standard)	Reference Standards Phosphodiesterase (PDE) Apoptosis	Cardiovascular Disease Cancer
Anagrelide (hydrochloride) (Standard) is the analytical standard of Anagrelide (hydrochloride). This product is intended for research and analytical applications. Anagrelide hydrochloride (BL4162A) is a potent inhibitor of phosphodiesterase type III (PDE3) (IC50=36 nM). Anagrelide hydrochloride, an imidazoquinazoline derivative, acts as an inhibitor of platelet aggregation. Anagrelide hydrochloride inhibits bone marrow megakaryocytopoiesis. Anagrelide hydrochloride decreases gastrointestinal stromal tumor (GIST) cell proliferation and promotes their apoptosis in vitro. Anagrelide hydrochloride is a platelet-lowering agent and plays in the antithrombopoietic action .

HY-B0523S

Anagrelide-13C2,15N,d2	Apoptosis Phosphodiesterase (PDE) Isotope-Labeled Compounds	Cardiovascular Disease Cancer
Anagrelide- ¹³C₂, ¹⁵N,d₂ is ¹⁵N and deuterated labeled Anagrelide (HY-B0523). Anagrelide is a potent inhibitor of phosphodiesterase type III (PDE3) (IC₅₀=36 nM). Anagrelide, an imidazoquinazoline derivative, acts as an inhibitor of platelet aggregation. Anagrelide inhibits bone marrow megakaryocytopoiesis. Anagrelide decreases gastrointestinal stromal tumor (GIST) cell proliferation and promotes their apoptosis in vitro. Anagrelide is a platelet-lowering agent and plays in the antithrombopoietic action .

HY-100164R

SDZ-MKS 492 (Standard) MKS 492 (Standard)	Phosphodiesterase (PDE) Reference Standards	Inflammation/Immunology
SDZ-MKS 492 (Standard) is the analytical standard of SDZ-MKS 492 (HY-100164). This product is intended for research and analytical applications. SDZ-MKS 492 (MKS 492) is a selective inhibitor of cyclic GMP-inhibited phosphodiesterase (type III PDE). SDZ-MKS 492 inhibits antigen- or platelet activating factor (PAF)-induced bronchoconstriction and allergic reactions in guinea pigs and rats .

HY-106830

Pelrinone	Phosphodiesterase (PDE)	Cardiovascular Disease
Pelrinone is an orally active cardiotonic agent and **PDE III inhibitor with an IC₅₀ of 36 μM. Pelrinone elevates intracellular cAMP** levels. The action of Pelrinone is independent of β-adrenergic receptors, and it does not inhibit Na ⁺/K ⁺-ATPase. Pelrinone exerts positive inotropic and vasodilatory effects. Pelrinone inhibits platelet aggregation, reduces thrombus formation, and exerts weak anticoagulant activity without altering hematocrit or circulating platelet counts. Pelrinone can be used in research related to congestive heart failure and coronary thrombosis .

HY-101693AR

Senazodan hydrochloride (Standard) MCI 154 hydrochloride (Standard)	Phosphodiesterase (PDE) Reference Standards	Cardiovascular Disease
Senazodan (hydrochloride) (Standard) is the analytical standard of Senazodan (hydrochloride) (HY-101693A). This product is intended for research and analytical applications. Senazodan (MCI 154) (hydrochloride), as a Ca2+ sensitiser, shows inhibition effect on PDE III .

HY-108621R

RS-25344 hydrochloride (Standard)	Reference Standards Phosphodiesterase (PDE)	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
RS-25344 hydrochloride (Standard) is the analytical standard of RS-25344 (hydrochloride) (HY-108621). This product is intended for research and analytical applications. RS-25344 hydrochloride is a selective cAMP-phosphodiesterase 4 (PDE 4; PDE IV) inhibitor with an IC₅₀ of 0.28 nM in human lymphocytes. RS-25344 hydrochloride has only weak inhibitory effects on PDE I, II, III (IC₅₀ of >100 μM, 160 μM, 330 μM, respectively). RS-25344 hydrochloride has anti-inflammatory, memory- and cognition enhancing, and antineoplastic effects .

HY-135746S

OR-1896-d3	Isotope-Labeled Compounds Phosphodiesterase (PDE) Apoptosis Potassium Channel Drug Metabolite	Cardiovascular Disease
OR-1896-d₃ is the deuterium labeled OR-1896 (HY-135746). OR-1896 is an active long-lived metabolite of Levosimendan. OR-1896 is a highly selective phosphodiesterase (PDE) III isoform inhibitor and a powerful vasodilator. OR-1896 can open ATP-sensitive K+ channels and has Ca2+-sensitizing effect. OR-1896 mitigates cardiomyocyte apoptosis, cardiac remodeling and myocardial inflammation .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B1514R

Allantoic acid (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite
Anagrelide (hydrochloride) (Standard) is the analytical standard of Anagrelide (hydrochloride). This product is intended for research and analytical applications. Anagrelide hydrochloride (BL4162A) is a potent inhibitor of phosphodiesterase type III (PDE3) (IC50=36 nM). Anagrelide hydrochloride, an imidazoquinazoline derivative, acts as an inhibitor of platelet aggregation. Anagrelide hydrochloride inhibits bone marrow megakaryocytopoiesis. Anagrelide hydrochloride decreases gastrointestinal stromal tumor (GIST) cell proliferation and promotes their apoptosis in vitro. Anagrelide hydrochloride is a platelet-lowering agent and plays in the antithrombopoietic action .

Cat. No.	Product Name	Chemical Structure

HY-B0523S

Anagrelide-13C2,15N,d2
Anagrelide- ¹³C₂, ¹⁵N,d₂ is ¹⁵N and deuterated labeled Anagrelide (HY-B0523). Anagrelide is a potent inhibitor of phosphodiesterase type III (PDE3) (IC₅₀=36 nM). Anagrelide, an imidazoquinazoline derivative, acts as an inhibitor of platelet aggregation. Anagrelide inhibits bone marrow megakaryocytopoiesis. Anagrelide decreases gastrointestinal stromal tumor (GIST) cell proliferation and promotes their apoptosis in vitro. Anagrelide is a platelet-lowering agent and plays in the antithrombopoietic action .

Anagrelide-13C2,15N,d2

Anagrelide- ¹³C₂, ¹⁵N,d₂ is ¹⁵N and deuterated labeled Anagrelide (HY-B0523). Anagrelide is a potent inhibitor of phosphodiesterase type III (PDE3) (IC₅₀=36 nM). Anagrelide, an imidazoquinazoline derivative, acts as an inhibitor of platelet aggregation. Anagrelide inhibits bone marrow megakaryocytopoiesis. Anagrelide decreases gastrointestinal stromal tumor (GIST) cell proliferation and promotes their apoptosis in vitro. Anagrelide is a platelet-lowering agent and plays in the antithrombopoietic action .

HY-135746S

OR-1896-d3
OR-1896-d₃ is the deuterium labeled OR-1896 (HY-135746). OR-1896 is an active long-lived metabolite of Levosimendan. OR-1896 is a highly selective phosphodiesterase (PDE) III isoform inhibitor and a powerful vasodilator. OR-1896 can open ATP-sensitive K+ channels and has Ca2+-sensitizing effect. OR-1896 mitigates cardiomyocyte apoptosis, cardiac remodeling and myocardial inflammation .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks